Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
A 28.91 0.40% 0.12
ALKS closed down 0.79 percent on Monday, January 30, 2023, on 79 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 15
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.40%
Overbought Stochastic Strength -0.40%
Up 3 Days in a Row Strength -0.40%
Up 4 Days in a Row Strength -0.40%
NR7 Range Contraction 1.42%
Narrow Range Bar Range Contraction 1.42%
Stochastic Reached Overbought Strength 1.42%
Inside Day Range Contraction 1.42%
Overbought Stochastic Strength 1.42%
Up 3 Days in a Row Strength 1.42%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alkermes plc Description

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Alcohol Diabetes Surgery Hypertension Chemotherapy Opioids Spas Lipid Schizophrenia Multiple Sclerosis Cholesterol Neurochemistry Organic Chemistry Depressive Disorder Morphinans Nausea Constipation Angina Hyperactivity Disorder I Diabetes Obsessive Compulsive Disorder Treatment Of Schizophrenia Cachexia Ii Diabetes Atypical Antipsychotics Cocaine Opioid Receptors Spasticity Transplant Rejection Treatment Of Multiple Sclerosis Luvox Cr Opioid Antagonists Opioid Induced Constipation Pharmaceutical Wholesalers Zanaflex

Is ALKS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 32.79
52 Week Low 21.75
Average Volume 1,339,328
200-Day Moving Average 26.21
50-Day Moving Average 25.87
20-Day Moving Average 27.32
10-Day Moving Average 28.18
Average True Range 0.80
RSI 63.64
ADX 38.57
+DI 36.33
-DI 10.54
Chandelier Exit (Long, 3 ATRs) 26.89
Chandelier Exit (Short, 3 ATRs) 27.30
Upper Bollinger Bands 29.48
Lower Bollinger Band 25.16
Percent B (%b) 0.84
BandWidth 15.80
MACD Line 0.84
MACD Signal Line 0.75
MACD Histogram 0.0877
Fundamentals Value
Market Cap 4.58 Billion
Num Shares 159 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -24.61
Price-to-Sales 2.50
Price-to-Book 2.72
PEG Ratio -1057.29
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.59
Resistance 3 (R3) 29.67 29.47 29.46
Resistance 2 (R2) 29.47 29.27 29.44 29.41
Resistance 1 (R1) 29.13 29.14 29.04 29.06 29.37
Pivot Point 28.94 28.94 28.89 28.90 28.94
Support 1 (S1) 28.60 28.73 28.50 28.52 28.21
Support 2 (S2) 28.40 28.61 28.37 28.17
Support 3 (S3) 28.06 28.40 28.12
Support 4 (S4) 27.99